Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression

Redox Biology

Volumn 10, Issue , 2016, Pages 168-178

  Chen, Hua ^a   Cao, Gang ^c   Chen, Dan Qian ^a   Wang, Ming ^a   Vaziri, Nosratola D ^b   Zhang, Zhi Hao ^d   Mao, Jia Rong ^e   Bai, Xu ^f   Zhao, Ying Yong ^a  

^a NORTHWEST UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e Second Affiliated Hospital of Shaanxi University of Chinese Medicine   (China)

^f Waters Technologies Shanghai Ltd   (China)

Author keywords

Biomarker; Chronic kidney disease; Inflammation; Lipid metabolism; Metabolomics; Renal fibrosis

Indexed keywords

12 KETODEOXYCHOLIC ACID; BIOLOGICAL MARKER; CHOLIC ACID DERIVATIVE; CREATININE; DOCOSAHEXAENOIC ACID; ERGONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDICAN; IRBESARTAN; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLETHANOLAMINE; NATURAL PRODUCT; TAUROCHENODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; UREA; URIC ACID; ADENINE; ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; INTERSTITIAL NEPHRITIS; LIPID METABOLISM; MALE; METABOLIC DISORDER; METABOLITE; METABOLOMICS; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT; UPREGULATION; UREA BLOOD LEVEL; VALIDATION STUDY; ANIMAL; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; DISEASE EXACERBATION; DISEASE MODEL; METABOLISM; PROCEDURES;

ADENINE; ANIMALS; ARISTOLOCHIC ACIDS; BIOMARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; LIPID METABOLISM; MALE; METABOLOMICS; NEPHRITIS, INTERSTITIAL; OXIDATION-REDUCTION; RATS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84991609065     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2016.09.014     Document Type: Article

References (38)

1. [1] Weiss, R.H., Kim, K., Metabolomics in the study of kidney diseases. Nat. Rev. Nephrol. 8:1 (2011), 22–33.
2. [2] Zhao, Y.Y., et al. Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin. Chim. Acta 413:19–20 (2012), 1438–1445.
3. [3] Posada-Ayala, M., et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int. 85:1 (2014), 103–111.
4. [4] Zhang, Z.H., et al. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Sci. Rep., 5, 2015, 14472.
5. E. J. Proteome Res. 12:2 (2013), 692–703.
6. [6] Zhao, Y.Y., et al. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin. Chim. Acta 413:5–6 (2012), 642–649.
7. [7] Debelle, F.D., Vanherweghem, J.L., Nortier, J.L., Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74:2 (2008), 158–169.
8. [8] Zhao, Y.Y., Lin, R.C., Metabolomics in nephrotoxicity. Adv. Clin. Chem. 65 (2014), 69–89.
9. [9] Zhao, Y.Y., et al. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci. Rep., 5, 2015, 12936.
10. [10] Kieffer, D.A., et al. Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am. J. Physiol. Ren. Physiol. 310:9 (2016), F857–F871.
11. [11] Zhao, Y.Y., et al. Serum metabonomics study of adenine-induced chronic renal failure rat by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers 17:1 (2012), 48–55.
12. [12] Zhao, Y.Y., et al. UPLC based metabolomics applications for discovering biomarkers of diseases in clinical chemistry. Clin. Biochem. 47:15 (2014), 16–26.
13. E. J. Pharm. Biomed. Anal. 81–82 (2013), 202–209.
14. [14] Zhao, Y.Y., et al. Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chem. Biol. Interact. 220 (2014), 181–192.
15. [15] Zhao, Y.Y., et al. Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. Bioanalysis 7:6 (2015), 685–700.
16. [16] Zhao, Y.Y., et al. A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/HDMS. PloS One, 9(12), 2014, e115467.
17. [17] Zhao, Y.Y., et al. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. PloS One, 8(3), 2013, e59617.
18. [18] Zhang, Z.H., et al. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Sci. Rep., 6, 2016, 22151.
19. [19] Xia, J., Wishart, D.S., MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucleic Acids Res. 38 (2010), W71–W77.
20. [20] Karnovsky, A., et al. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics 28:3 (2012), 373–380.
21. E data collection technique. Biomarkers 17:8 (2012), 721–729.
22. [22] Ding, Y.J., Chen, Y.H., Developmental nephrotoxicity of aristolochic acid in a zebrafish model. Toxicol. Appl. Pharmacol. 261:1 (2012), 59–65.
23. [23] Tsai, K.D., et al. Downregulation of connective tissue growth factor by LPS/IFN-γ-induced nitric oxide is reversed by aristolochic acid treatment in glomerular mesangial cells via STAT-1α and NF-κB signaling. Chem. Biol. Interact. 210 (2014), 86–95.
24. [24] Yu, F.Y., et al. Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells. Toxicol. Vitro 25:4 (2011), 810–816.
25. [25] Wu, J., et al. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. Toxicology 318 (2014), 22–31.
26. [26] Zhao, Y.Y., Vaziri, N.D., Lin, R.C., Lipidomics: new insight into kidney disease. Adv. Clin. Chem. 68 (2015), 149–171.
27. E application in disease biomarker discovery: the discoveries in proteomics to metabolomics. Chem. Biol. Interact. 215 (2014), 7–16.
28. [28] El-Beshbishy, H.A., et al. Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes. Eur. J. Pharmacol. 668:1–2 (2011), 278–284.
29. [29] Shidfar, F., et al. Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and ma-londialdehyde in type 2 diabetes patients. East Mediterr. Health J. 14:2 (2008), 305–315.
30. [30] Kaler, B., et al. Are bile acids involved in the renal dysfunction of obstructive jaundice? An experimental study in bile duct ligated rats. Ren. Fail. 26:5 (2004), 507–516.
31. [31] Zhang, Z.H., et al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J. Proteome Res., 2016, 10.1021/acs.jproteome.6b00583.
32. [32] Vaziri, N.D., et al. Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int. 83:2 (2013), 308–315.
33. [33] Wong, J., et al. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am. J. Nephrol. 39:3 (2014), 230–237.
34. [34] Hood, C.J., Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients. Nephrology 20:4 (2015), 250–256.
35. [35] Chu, L., Mechanism underlying an elevated serum bile acid level in chronic renal failure patients. Int. Urol. Nephrol. 7:2 (2015), 345–351.
36. [36] Levi, M., Role of bile acid-regulated nuclear receptor FXR and G protein-coupled receptor TGR5 in regulation of cardiorenal syndrome (cardiovascular disease and chronic kidney disease). Hypertension 67:6 (2016), 1080–1084.
37. [37] Mosińska, P., et al. The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. Ther. Adv. Gastroenterol. 8:5 (2015), 278–284.
38. [38] Hu, Z., et al. Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats. Kidney Blood Press. Res. 36:1 (2012), 85–97.